Should I Buy LUNG? LUNG 2026 Analysis

Should You Buy Pulmonx Corp (LUNG) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.500

1 Day change

3.45%

52 Week Range

9.370

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: price is in a clear downtrend and has slipped below the near-term support zone (S1=1.512), increasing odds of further downside toward S2 (~1.391).
Oversold RSI (6)=12 can trigger sharp dead-cat bounces, but momentum (MACD) is still deteriorating, so the “oversold” condition is not yet a reliable entry by itself.
Options flow is mixed-to-bearish near term (put-heavy volume) and implied volatility is extremely elevated, suggesting the market is braced for big moves (often around earnings).
Best stance now: avoid new longs until price reclaims and holds above ~1.51–1.71, or momentum indicators start turning up.

Technical Analysis

Trend: Bearish (SMA_200 > SMA_20 > SMA_5) confirms persistent downside pressure.
Momentum: MACD histogram -0.033 and negatively expanding = bearish momentum strengthening (not a reversal signal).
Oscillators: RSI_6 = 12.263 = deeply oversold; bounce potential exists but remains counter-trend.
Key levels:
- Immediate resistance: Pivot 1.707, then R1 1.901.
- Supports: S1 1.512 (already broken), next S2 1.391 (next downside magnet).
Pattern-based odds (provided): ~80% chance of -0.31% next day; modest +3.42% next month—suggests near-term weakness with only a mild probabilistic rebound later.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Sentiment snapshot: Open-interest PCR 0.82 (more call positioning than puts) is mildly bullish, but volume PCR 2.5 (put volume dominating) is near-term bearish/defensive.
Activity: Today’s volume 35; today vs 30D avg volume 13.26x = unusual options attention.
Volatility: 30D IV 211.51% vs historical vol 57.84% (IV extremely rich); IV percentile 82.47 indicates options are expensive and the market is pricing large moves.
Positioning: Call OI 5,241 vs Put OI 4,314; total OI 9,555 with elevated participation—often consistent with event-driven hedging/speculation.

Technical Summary

Sell

Buy

Positive Catalysts

on 2026-02-23 after hours can act as a volatility catalyst if results/forward commentary surprise positively.

Neutral/Negative Catalysts

with bearish moving averages—trend remains firmly down.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $21.502M, +5.47% YoY (modest growth).
Profitability: Net income -$13.957M (slightly worse YoY by -1.32%); EPS -0.34 (worse YoY by -5.56%)—losses persist.
Margins: Gross margin 74.65%, +1.29% YoY (a clear operational positive, but not yet offsetting opex).
Setup into earnings: with continued losses and high IV, the market is pricing meaningful event risk around the 2026-02-23 report.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price-target change data was provided in the dataset, so no confirmed recent trend can be stated.
Wall Street-style pros (based on fundamentals shown): improving gross margin, modest revenue growth, and notable hedge-fund accumulation.
Wall Street-style cons: persistent losses/negative EPS, micro-cap risk profile, and a technically broken chart (downtrend + support break), which typically keeps institutional buyers cautious until stabilization.

5 Analyst Rating

Wall Street analysts forecast LUNG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUNG is 4.1 USD with a low forecast of 2.5 USD and a high forecast of 6 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

2 Hold

0 Sell

Moderate Buy

Current: 1.450

Low

2.5

Averages

4.1

High

Current: 1.450

Low

2.5

Averages

4.1

High

Lake Street

Buy

downgrade

$8 -> $4

AI Analysis

2025-10-28

Reason

Lake Street

Price Target

$8 -> $4

AI Analysis

2025-10-28

downgrade

Buy

Reason

Lake Street lowered the firm's price target on Pulmonx to $4 from $8 and keeps a Buy rating on the shares. While the return of former CEO Glen French and CFO Derrick Sung was "certainly surprising," the firm believes the Street will view the return of prior leadership positively, the analyst tells investors. The firm, which continues to think shares are attractive given the "vast clinical verification/proof of concept of Zephyr valves," and the market opportunity and new product pipeline, notes that its lowered price target still "supports an approximate double from after-hours prices."

Citi

Neutral

downgrade

2025-05-22

Reason

Citi

Price Target

2025-05-22

downgrade

Neutral

Reason

Citi lowered the firm's price target on Pulmonx to $4.15 from $6.50 and keeps a Neutral rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LUNG

Unlock Now

LUNG Should I Buy

LUNG Should I Buy

Should You Buy Pulmonx Corp (LUNG) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch